Dr. Jeffrey Langland

Publications

1.
Nelson EO, Kozin AF, Ruiz G, Lasku A, Langland JO. Treatment of athlete’s plantar warts using a botanical blend: a case report. Altern Ther Health Med. 2017 Feb 27;
2.
Arndt WD, White SD, Johnson BP, Huynh T, Liao J, Harrington H, et al. Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus. Virology. 2016 Oct;497:125–35.
3.
Wolf J, Deng Y, Langland J. Treatment of medically refractory chronic daily vomiting with acupuncture and Chinese herbal medicine: a case report. Journal of Chinese Medicine. 2016 Jun;111:31–6.
4.
Ferreira V., Ruiz G., Jacobs BL., Denzler K., Waters R., Chamberlain R., Proefrock KJ., Langland JO. Treatment of Verruca vulgaris (common warts) with a synergistic botanical blend. NDNR. 2016 May;
5.
Denzler KL, Huynh TP, Jacobs BL, Langland JO. Melissa officinalis extract inhibits herpes simplex virus-I glycoprotein B interaction with heparin sulfate. Herbal Medicine:  Open Access. 2016 Apr;
6.
Ferreira V., Dickerson W., Farr D., Barraza M., Banker R., Dutton J., Cervigni M., Willhauck M., Tifre L., Mayman S., Stone S., Bushman S., Hull G., Morgan R., Hoover T., Mittman A., Sparks L., Smithers J., Miles D., Calvert D., Langland J. The Effect of botanical tinctures and essential oils on the growth and morphogenesis of Candida albicans. Herbal Medicine:  Open Access. 2016 Mar;
7.
Ruiz GG, Nelson EO, Kozin AF, Turner TC, Waters RF, Langland JO. A Lack of bioactive predictability for marker compounds commonly used for herbal medicine standardization. PLoS ONE. 2016;11(7):e0159857.
8.
Denzler K, Moore J, Harrington H, Morrill K, Huynh T, Jacobs B, et al. Characterization of the physiological response following in vivo administration of Astragalus membranaceus. Evidence-Based Complementary and Alternative Medicine. 2016;2016:1–13.
9.
Allen, J., Deng, Y., and Langland, J.O. Treatment of chronic migraine pain with acupuncture and herbal medication. Journal of Chinese Medicine. 2016;110:18–22.
10.
Wolf J, Sparks L, Deng Y, Langland J. Restoration of function With acupuncture following severe traumatic brain injury: a case report. Glob Adv Health Med. 2015 Nov;4(6):52–7.
11.
Grise DE, McAllister HM, Langland J. Improved clinical outcomes of patients with type 2 diabetes mellitus utilizing integrative medicine: a case report. Glob Adv Health Med. 2015 May;4(3):57–61.
12.
Virdee K, Musset J, Baral M, Cronin C, Langland J. Food-specific IgG Antibody-guided Elimination Diets Followed by Resolution of Asthma Symptoms and Reduction in Pharmacological Interventions in Two Patients: A Case Report. Glob Adv Health Med. 2015 Jan;4(1):62–6.
13.
Wheeler M., Oskin J., Langland J. Alternating Symptoms in the Homoeopathic Treatment of Bipolar Disorder. Platinum Metallicum: A Case Report. American Journal of Homeopathic Medicine. 2015 Winter;108(4):145–53.
14.
Ferreira, V., Jacobs, B.L., Denzler, K., Waters, R., Chamberlain, R., Proefrock, K.J., and Langland, J.O., Jacobs BL, Waters RF, Chamberlain R., Proefrock K.J., Langland JO. Treatment of Herpes Zoster with botanical interventions: case report. NDNR. 2015;
15.
Swanson M, Langland JO. Voices of naturopathic research. NDNR. 2014 Aug;
16.
Snowden R, Harrington H, Morrill K, Jeane L, Garrity J, Orian M, et al. A comparison of the anti-Staphylococcus aureus activity of extracts from commonly used medicinal plants. J Altern Complement Med. 2014 May;20(5):375–82.
17.
Morrill K, May K, Leek D, Langland N, Jeane LD, Ventura J, et al. Spectrum of antimicrobial activity associated with ionic colloidal silver. J Altern Complement Med. 2013 Mar;19(3):224–31.
18.
Arneson, D., Black, S., Waters, R., Langland, J.O., and Gelinas, B. Liquid CMO vs. Fibromyalgia: an open clinical pilot study using a liquid emulsion form of cetyl myristoleate. NDNR. 2012 Jul;
19.
Arndt W, Mitnik C, Denzler KL, White S, Waters R, Jacobs BL, et al. In Vitro Characterization of a nineteenth-century therapy for smallpox. Vermund SH, editor. PLoS ONE. 2012 Mar 9;7(3):e32610.
20.
Langland JO, Langland EV. Fauna of a 400-million-year-old coral reef in Arizona. Rocks & Minerals. 2012 Jan 31;87(1):40–4.
21.
Ameson D, Black S, Gelinas B, Langland J, Waters R, Black S., Gelinas B., Langland J., Waters R. Novel fibromyalgia therapy:  Open pilot study using a liquid emulsion form of cetyl myrisoleate. NDNR. 2012;8:1–6.
22.
White SD, Conwell K, Langland JO, Jacobs BL. Use of a negative selectable marker for rapid selection of recombinant vaccinia virus. BioTechniques. 2011 May;50(5):303–9.
23.
Willis KL, Langland JO, Shisler JL. Viral double-stranded RNAs from vaccinia virus early or intermediate gene transcripts possess PKR activating function, resulting in NF-kappaB activation, when the K1 protein is absent or mutated. J Biol Chem. 2011 Mar 11;286(10):7765–78.
24.
Denzler KL, Waters R, Jacobs BL, Rochon Y, Langland JO. Regulation of inflammatory gene expression in PBMCs by immunostimulatory botanicals. PLoS ONE. 2010 Sep 3;5(9):e12561.
25.
Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 2009 Oct;84(1):1–13.
26.
Zhang P, Langland JO, Jacobs BL, Samuel CE. Protein kinase PKR-dependent activation of mitogen-activated protein kinases occurs through mitochondrial adapter IPS-1 and is antagonized by vaccinia virus E3L. J Virol. 2009 Jun;83(11):5718–25.
27.
Jentarra GM, Heck MC, Youn JW, Kibler K, Langland JO, Baskin CR, et al. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine. 2008 Jun 2;26(23):2860–72.
28.
Ye Y, Hauns K, Langland JO, Jacobs BL, Hogue BG. Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist. J Virol. 2007 Mar;81(6):2554–63.
29.
Langland JO, Kash JC, Carter V, Thomas MJ, Katze MG, Jacobs BL. Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins. J Virol. 2006 Oct;80(20):10083–95.
30.
Langland JO, Cameron JM, Heck MC, Jancovich JK, Jacobs BL. Inhibition of PKR by RNA and DNA viruses. Virus Res. 2006 Jul;119(1):100–10.
31.
Torrence PF, editor. Viral Countermeasures to the Host Interferon Response: Role of the Vaccinia Virus E3L and K3L Genes. In: Antiviral drug discovery for emerging diseases and bioterrorism threats. Hoboken, N.J: Wiley-Interscience; 2005. p. 353–78.
32.
Langland JO, Jacobs BL. Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L. Virology. 2004 Jul 1;324(2):419–29.
33.
Vijaysri S, Talasela L, Mercer AA, Mcinnes CJ, Jacobs BL, Langland JO. The Orf virus E3L homologue is able to complement deletion of the vaccinia virus E3L gene in vitro but not in vivo. Virology. 2003 Sep 15;314(1):305–14.
34.
Langland JO, Kao P, Jacobs BL. Regulation of IL-2 gene expression and nuclear factor-90 translocation in vaccinia virus-infected cells. J Interferon Cytokine Res. 2003 Sep;23(9):489–500.
35.
Langland JO, Jacobs BL. The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Virology. 2002 Jul 20;299(1):133–41.
36.
He Y, Tan SL, Tareen SU, Vijaysri S, Langland JO, Jacobs BL, et al. Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J Virol. 2001 Jun;75(11):5090–8.
37.
Langland JO, Kao PN, Jacobs BL. Nuclear factor-90 of activated T-cells: A double-stranded RNA-binding protein and substrate for the double-stranded RNA-dependent protein kinase, PKR. Biochemistry. 1999 May 11;38(19):6361–8.
38.
Jacobs BL, Langland JO, Brandt T. Characterization of viral double-stranded RNA-binding proteins. Methods. 1998 Jul;15(3):225–32.
39.
Langland J, Langland L, Roth D. Differential localization and accumulation of the plant double stranded RNA-dependent protein kinase during virus infection. Plant Physiology and Biochemistry. 1998 May;36(5):395–400.
40.
Rager KJ, Langland JO, Jacobs BL, Proud D, Marsh DG, Imani F. Activation of antiviral protein kinase leads to immunoglobulin E class switching in human B cells. J Virol. 1998 Feb;72(2):1171–6.
41.
Jacobs BL, Langland JO. Reovirus Sigma3 Protein: dsRNA-Binding and Inhibition of PKR. Current Topics in Microbiology and Immunology. 1998;185–96.
42.
Langland JO, Langland L, Zeman C, Saha D, Roth DA. Developmental regulation of a plant encoded inhibitor of eukaryotic initiation factor 2 alpha phosphorylation. Plant J. 1997 Aug;12(2):393–400.
43.
Kibler KV, Shors T, Perkins KB, Zeman CC, Banaszak MP, Biesterfeldt J, et al. Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J Virol. 1997 Mar;71(3):1992–2003.
44.
Karupiah G, editor. Viral inhibitors of interferon action: inhibitors of the PKR and 2’5’ oligoadenylate synthetase/RNase L pathways. In: Gamma Interferon in Antiviral Defense. New York Berlin Heidelberg London Paris Tokyo Hong Kong Barcelona Budapest: Springer; 1997. (Medical intelligence unit).
45.
Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology. 1996 May 15;219(2):339–49.
46.
Langland JO, Langland LA, Browning KS, Roth DA. Phosphorylation of plant eukaryotic initiation factor-2 by the plant-encoded double-stranded RNA-dependent protein kinase, pPKR, and inhibition of protein synthesis in vitro. J Biol Chem. 1996 Feb 23;271(8):4539–44.
47.
Roth, D. A. Landgland J.O. Functional significance of plant encoded dsRNA dependent protein activity in the regulation of protein synthesis. Current Top in Plant Biochem  Mol  Biol. 1996;15:77–8.
48.
Langland, J.0., Langland, L.A. and Roth, D.A. Polyanion regulation of the plant-encoded dsRNA-dependent protein kinase, pPKR. Plant Phys and Biochem. 1996;34:521–6.
49.
Langland JO, Jin S, Jacobs BL, Roth DA. Identification of a plant-encoded analog of PKR, the mammalian double-stranded RNA-dependent protein kinase. Plant Physiol. 1995 Jul;108(3):1259–67.
50.
Langland JO, Pettiford SM, Jacobs BL. Nucleic acid affinity chromatography: preparation and characterization of double-stranded RNA agarose. Protein Expr Purif. 1995 Feb;6(1):25–32.
51.
Langland JO, Pettiford S, Jiang B, Jacobs BL. Products of the porcine group C rotavirus NSP3 gene bind specifically to double-stranded RNA and inhibit activation of the interferon-induced protein kinase PKR. J Virol. 1994 Jun;68(6):3821–9.
52.
Park H, Davies MV, Langland JO, Chang HW, Nam YS, Tartaglia J, Paoletti E, Jacobs BL, Kaufman RJ, Venkatesan S. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. PNAS. 1994;91(11):4713–7.
53.
Park, H., Davies, M.V., Langland, J.0., Chang, H.W., Nam, Y.S., Tartaglia, J., Paoletti, E., Jacobs, B.L. Kaufman, R.J. and Venkatesan, S. A Cellular protein that binds several structured viral RNAs is an inhibitor of the interferon-induced PKR protein kinase in vitro and in vivo. Proceedings of the National Academy of Sciences. 1994;91:4713–7.
54.
Langland JO, Jacobs BL. Cytosolic double-stranded RNA-dependent protein kinase is likely a dimer of partially phosphorylated Mr = 66,000 subunits. J Biol Chem. 1992 May 25;267(15):10729–36.

Patents
 
1.
Langland JO. A method for inserting genetic material into genomic DNA. M10–168L.
2.
Langland JO. Carnivorous botanical extracts with antiviral, anticarcinogenic, analgesic and antipruritic properties for the treatment of disease. M13–037L.
3.
Langland JO. Cell death and oncolytic vaccinia virus mutants. D16-060.
4.
Langland JO. Extract of the botanical Melissa officinalis with antiviral activity against ebola virus. M15–180L.
5.
Langland JO. Method and compositions for use of carnivorous plant extracts in the treatment of poxvirus infections. M9–087L.
6.
Langland JO. Mutants of vaccinia virus as oncolytic agents. M3–091L, 2003.
7.
Langland JO. Mutated poxviruses which affect dsRNA-binding as vaccine and gene therapy vectors. 6,750,043 and 6,942,955, 2005.
8.
Langland JO. Poxviruses containing novel genes for PKR inhibitors in place of E3L as vaccine and gene therapy vectors. M1-026, 2000.
9.
Langland JO. Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein. 5,990,388, 1999.

Conference Presentations

1.
Turner T., Ruiz G., and Langland L.O. Treatment of Herpes Virus-Associated Lesions Using a Synergistic Botanical Blend. Arizona Naturopathic Medical Association. Salt Lake City, UT; 2016.
2.
Turner T., Ruiz G., and Langland L.O. A Botanical Extract with Broad Anti-Viral and Oncolytic Activity. International Congress on Naturopathic Medicine. Barcelona, Spain; 2016.
3.
Ruiz G., Turner T. and Langland J.O. Sarracenia Purpurea:  A Botanical Extract with Broad Anti-Viral and Oncolytic Activity. Arizona Naturopathic Medical Association. Salt Lake City, UT; 2016.
4.
Ruiz G., Turner T. and Langland J.O. Bacterial Resistance to Antimicrobial Botanicals. International Congress on Naturopathic Medicine. Barcelona, Spain; 2016.
5.
Ruiz G. and Langland J.O. Botanical Medicine:  The Evoluationary Development of Antiviral Activity in Carnivorous Plants. Ancestral Health Symposium. Boulder, CO; 2016.
6.
Langland J.0. Mechanistic Botanical Medicine:  Defining Anti-Cancer, Anti-Viral and Anti-Bacterial Properties and Standardization. Southwest Conference on Botanical Medicine. 2016.
7.
Dharti P. & Langland J.O. Treatment of Herpes Virus Associated Lesions Using a Synergistic Botanical Blend.  American Academy of Oral and Maxillofacial Pathology. Cincinnati, Ohio; 2016.
8.
Ruiz G., Turner T., Sparks L. and Langland J.O. Bacterial Resistance to Antimicrobial Botanicals. Society for the Advancement of Chicanos/Hispanics and Native Americans in Science. 2015.
9.
Ruiz G., Turner T., Sparks L. and Langland J.O. Bacterial Resistance to Antimicrobial Botanicals. American Association of Naturopathic Physicians. Oakland, CA; 2015.
10.
Ruiz G. and Langland J.O. A Botanical Extract with Broad Anti-Viral and Oncolytic Activity. Society for Integrative Oncology. Boston, Massachusetts; 2015.
11.
Langland J.0. Understanding the Antimicrobial Potential of Botanicals:  Unlocking the Mechanisms of Action and the Need for Proper Use. Arizona Naturopathic Medical Association. Scottsdale, AZ; 2015.
12.
Jacobs B., Denzer K. and Langland J. An Herbal Extract with Broad Antiviral Activity. Viruses and Cells Gordon Conference. Girona, Spain; 2015.
13.
Harrington H., Langland J. and Jacobs B. The Role of Vaccinia Virus E3L Protein in Regulating Programmed Cell Death. American Society for Virology. London, Canada; 2015.
14.
Langland J. and Alianza M. Antiviral Activity Associated with Botanical Medicine. Arizona BioIndustry Association. Phoenix, AZ; 2014.
15.
Harrington H., Langland J. and Jacobs B. The Role of Vaccinia Virus E3L Protein in Regulating Programmed Cell Death. International Poxvirus, Asfarvirus and Iridocirus Conference. Victoria, Canada; 2014.
16.
Harrington H., Langland J. and Jacobs B. The Role of the Vaccinia Virus E3L Protein in Regulating Programmed Cell Death. American Society for Virology. Ft. Collins, CO; 2014.
17.
Harrington H., and Langland J. Anti-Herpes Virus Activity Associated with Botanical Extracts from Melissa Officinalis. American Association of Naturopathic Physicians. Scottsdale, AZ; 2014.
18.
Ferreira V. and Langland J. Botanicals which Affect the Growth of Candida Albicans. American Association of Naturopathic Physicians. Scottsdale, AZ; 2014.
19.
Sparks L., Harrington H., Waters R., Rochon Y., and Langland J. Development of Bacterial Resistance to Antimicrobial Botanical Extracts. American Association of Naturopathic Physicians. Keystone, Colorado; 2013.
20.
Simonson X., Harrington H, Waters R. Rochon Y. and Langland J. Development of Bacterial Resistance to Antimicrobial Botanical Extracts. Bioindustry Convention. Tempe, AZ; 2013.
21.
Snowden R., Moore J., Harrington H., Leek D., Morrial K., Waters R., Denzler K. White S., Rochon Y., Langland J. Characterization of the Immune Response and Gene Expression Following Treatment with Astragalus membranaceus. American Medical Student Association. Houston, TX; 2012.
22.
Russell T., Harrington H., Morre J., Leek D., Waters R., Denzler K., White S., Rochon Y., Langland J. The Role of Bacterial Constituents in the Immunostimulatory Activity of Astragalus membranaceus. American Medical Student Association. Houston, TX; 2012.
23.
Olson V.A., Arndt W., Mitnik C., Denzler K.L., White S., Waters R., Jacobs B.L., Rochon Y.,Damon I.K. Langland J.O. In vitro Characterization of a Nineteenth Century Therapy for Smallpox. International Poxvirus, Asfarvirus and Iridocirus Conference. Salamanca, Spain; 2012.
24.
Langland J.O., Waters R.J., Bertram L., Rochon Y., Denzler K.L. Anti-Herpes Virus Activity Associated with Botanical Extracts from Melissa officinalis. American Society for Virology. Madison, WI; 2012.
25.
Huynh T., Muralina M., Hauns K., White S., Langland J, Jacobs B. The Role of Adenosine Deaminase Acting on RNA 1 (ADAR1) During Vaccinia Virus Infection. American Society for Virology. Madison, WI; 2012.
26.
Harrington H., Moore J.,Denzler K., Waters R., White S.., Morrill K., Leek D., Rochon Y. and Langland J. The Role of Endophytic Bacterial Lipopolysaccharide and Toll-Like Receptros in Astragalu membranaceus Induced Immune Response. Naturopathic Medical Students Association. Bellevue, WA; 2012.
27.
Harrington H., Moore J.,Denzler K., Waters R., White S.., Morrill K., Leek D., Rochon Y. and Langland J. Characterization of the Immune Response and Gene Expression Follwoing Treatment with Astragalus membranaceus.  Naturopathic Medical Students Association. Bellevue, WA; 2012.
28.
Harrington H., Moore J.,Denzler K., Waters R., White S.., Morrill K., Leek D., Rochon Y. and Langland J. Characterization of the Immune Response and Gene Expression Following Treatment with Astragalus membranaceus. American Association of Naturopathic Physicians. Bellevue, WA; 2012.
29.
Harrington H., Denzler K., Waters R., Jacobs B., Rochon Y. and Langland J. Anti-Herpes Virus Activity Associated with Botanical Extracts from Melissa Officinalis. American Association of Naturopathic Physicians. Bellevue, WA; 2012.
30.
Harrington H., Denzler K., Waters R., Jacobs B., Rochon Y. and Langland J. Anti-Herpes Virus Activity Associated with Botanical Extracts from Melissa Officinalis. American Society of Microbiology. Tempe, AZ; 2012.
31.
Harrington H., Denzler K., Waters R., Jacobs B., Rochon Y. and Langland J. Anti-Herpes Virus Activity Associated with Botanical Extracts fro Melissa officinalis. Naturopathic Medical Students Association. Bellevue, WA; 2012.
32.
Harrington H., Arndt W., Mitnik C., Denzler K., Waters R., White S., Jacobs B., Rochon Y., Olson V., Damon I., and Langland J. In vitro Characterization of a Nineteenth Century Therapy for Smallpos. National Medicinal Chemistry Symposium. Tucson, AZ; 2012.
33.
Blattman N., Langland J., White S., Jacobs B. Ability of E3 to Inhibit Innate Immune Signaling Independent of dsRNA and Z-DNA. American Society for Virology. Madison, WI; 2012.
34.
Snowden R., Harrington H., Leek D., Morrill K., Denzler K., Waters R., Jacobs B., Rochon Y., and Langland J. Gene Expression Analysis with Immunostimulatory Botanicals Both in vitro and in vivo. American Medical Student Association. Washington, D.C.; 2011.
35.
Snowden R.,  Arndt W., Denzler K., White S., Jacobs B., Waters R., Rochon Y., Langland J. Rediscovery of a 19th Century Therapy for Smallpox. Naturopathic Medical Students Association. Scottsdale, AZ; 2011.
36.
Harrington H., Moore J., Leek D., Waters R., Denzler K., White S., Rochon Y., Langland J. The Role of Bacterial Constituents in the Immunostimulatory Activity of Astragalus membranaceus. Naturopathic Medical Students Association. Scottsdale, AZ; 2011.
37.
Morrill K., Leek D., Langland J., Arndt W., Denzler K., Jacobs B., Waters R., Rochon Y. Rediscovery of a 19th Century Treatment for Smallpox. American Association of Naturopathic Physicians. Portland, OR; 2010.
38.
Leek D., Morrill K., Denzler K., Waters R., Jacobs B., Rochon Y., and Langland J. Correlation of Gene Expression with Physiological Responses by Immunostimulatory Botanicals. American Association of Naturopathic Physicians. Portland, OR; 2010.
39.
Lasku A., Waters R., and Langland J. Regulation of Immune Gene Expression by Immuno-Modulatory Botanicals. Experimental Biology. Anaheim, CA; 2010.
40.
Langland J., Arndt W., Jacobs B., Waters R., Rochon Y. Rediscovery of a 19th Century Treatment for Smallpox. International Poxvirus Conference. Sedona, AZ; 2010.
41.
Wong S., Cameron J., Langland J. and Jacobs B. Characterization of Vaccinia Virus E3L Mutants in Primary Epidermal Cells. American Society for Virology. Vancouver, Canada; 2009.
42.
Morrill K., May K., Leek D., Langland N., Jeane L., Ventura J., Skubisz C., Scherer S., Lopez E., Crocker E., Peters R., Oertle J., Nguyen K., Just S., Phair M.,  Humphrey M., Payne D., Jacobs B., Waters R, Langland J. Quantitative Evaluation of the Broad-Spectrum Anti-Microbial Activity of Colloidal Silver. American Association of Naturopathic Physicians. Tacoma, WA; 2009.
43.
Langland J., Waters R., and Rochon Y. Metabolic Genetic Expression Analysis of Astragalus sp. Herbal Extract on ex vivo Immuno-Stimulated Human Peripheral Blood Mononuclear Cells. American Association of Naturopathic Physicians. Scottsdale, AZ; 2008.
44.
Langland J.O., and Jacobs B.L. Viral Regulation of the PKR Innate Immune Response by Specific Proteolytic Processing. Cytokines in Health and Disease. San Francisco, CA; 2007.
45.
Langland J.O., and Jacobs B.L. Poxvirus Sequestration of Pathogen-Associated Molecular Patterns and the Host Response. Jaks, Stats and Immunity. Steamboat Springs, CO; 2007.
46.
Langland J.O., Kash J., Katze B. and Jacobs B.L. Poxvirus Sequestration of Pathogen-Associated Molecular Patterns and the Host Response. Cytokines. Vienna, Austria; 2006.
47.
Cameron J., Langland J.O., and Jacobs B.L. The Keratinocyte Response to Vaccinia Virus Induced Pathogen Associated Molecular Patterns. Cytokines. Vienna, Austria; 2006.
48.
Langland J.O. and Jacobs B.L. Poxviral Regulation of MAPK and IKK Signal Transduction in Response to Double-Stranded RNA. Signal Transduction in Viral Systems: ASM Conference. Savannah, GA; 2004.
49.
Langland J.O. and Jacobs B.L. Poxviral Regulation of Cellular Translation and Signal Transduction. Translational Control: Cold Spring Harbor Laboratory. Cold Spring Harbor, NY; 2004.
50.
Mitnik C., Jentarra G., Langland J.O. and Jacobs B.L. Ras Dependent Oncolysis by Vaccinia Virus. American Society for Virology. Davis, CA; 2003.
51.
Langland J.O., Kash J., Katze M., and Jacobs B.L. Poxviral Regulation of Host Gene Expression. American Society for Virology. Davis, CA; 2003.
52.
Muralinath M., Langland J.O., Brandt T., and Jacobs B.L. The Role of Z-DNA Binding of the Poxvirus E3L Gene Related to Pathogenesis. American Society for Virology. Madison, WI; 2001.
53.
Zeman C., Langland J.O. and Jacobs B.L. Expression of the Cellular PKR-Inhibitor, p67, Rescues Translation of an Interferon-Sensistive Vaccinia Virus Mutant. American Society for Virology. Ft. Collins, CO; 2000.
54.
Langland J.O. and Jacobs B.L. The Requirement of the Vaccinia Virus Interferon-Resistance Genes, E3L and K3L, for Viral Replication. Cold Spring Harbor Translation Control Meeting. Cold Spring Harbor, NY; 2000.
55.
Langland J.O. and Jacobs B.L. Regulation of PKR Activity by the Amino- and Carboxyl-Domains of the Vaccinia Virus Interferon-Resistance Gene, E3L. American Society for Virology. Ft. Collins, CO; 2000.
56.
Langland J.O. and Jacobs B.L. Regulation of eIF2a Phosphorylation by Distinct Amino- and Carboxyl-Domains of the Vaccinia Virus Interferon –Resistance gene, E3L. Cold Spring Harbor Translation Control Meeting. Cold Spring Harbor, NY; 2000.
57.
Langland J.O. and Jacobs B.L. Complimentary Roles of the Vaccinia Virus Inteferon-Resistance Genes, E3L and K3L. Poxvirus. Mt. Pelier, France; 2000.
58.
Perkins K., Langland J.O., Brandt T. and Jacobs B.L. Inhibition of dsRNA-Induced Apoptosis by the Baculovirus Caspase Inhibitor p35 but not the Vaccinia Virus Caspase Inhibitor SPI-2. American Society for Virology. Amhurst, MA; 1999.
59.
Langland J.O. and Jacobs B.L. Vaccinia Virus Interferon Sensitivity in the Presence of Viral Encoded PKR and 2’,5’-Oligoadenylate Synthetase Inhibitors. American Society for Virology. Amhurst, MA; 1999.
60.
Langland E.V., Langland J.O. and Jacobs B.L. Mechanism of Interferon Sensitivity of Vaccinia Virus Deleted of the Double-Stranded RNA Binding Protein, E3L. American Society for Virology. Amhurst, MA; 1999.
61.
Langland J.O. and Jacobs B.L. Constitutive Expression  of an Inhibitor of the dsRNA-Dependent Protein Kinase, PKR, in Kidney Cells. American Society for Virology. Vancouver, Canada; 1998.
62.
Langland J.O. and Jacobs B.L. Constitutive Expression  of an Inhibitor of the dsRNA-Dependent Protein Kinase, PKR, in Kidney Cells. American Society for Virology. Vancouver, Canada; 1998.
63.
Brandt T.A., Martens J., Langland J.O. and Jacobs B.L. Mutational Analysis of the dsRNA-Binding Protein Porcine Rotavirus P8. American Society for Virology. Vancouver, Canada; 1998.
64.
Langland J.O., Kao P.N. and Jacobs B.L. Regulation of the NF-AT Transcription Factor by Double-Stranded RNA. American Society for Virology. Bozeman, MT; 1997.
65.
Langland J.O., Kao P.N. and Jacobs B.L. Nuclear Factor of Activated T-Cells (NFAT): A Novel Double-Stranded RNA-Binding Protein and Substrate for the Double-Stranded RNA-Dependent Protein Kinase, PKR. Keystone Symposium. Taos, NM; 1997.
66.
Kibler K.V., Langland J.O., Shors T., Zeman C. and Jacobs B.L. A Double-Stranded RNA-Binding Protein is Necessary to Inhibit Induction of Apoptosis and for Interferon-Resistance in Vaccinia Virus Infected Cells. Keystone Symposium. Taos, NM; 1997.
67.
Roth D.A. and Langland J.0. Characterization of a Plant Analog of the Reticulocyte 67kDa Inhibitor of eIF-2a Phosphorylation. American Society for Virology. London, Canada; 1996.
68.
Langland J. O., Kao P.N. and Jacobs B.L. Nuclear Factor of Activated T-Cells: A Novel Double-Stranded RNA-Binding Protein and Substrate for the Double-Stranded RNA-Dependent Protein Kinase, PKR. American Society for Virology. London, Canada; 1996.
69.
Langland J.0., Langland L.A., Zeman C., Saha D. and Roth D.A. Developmental Regulation of a Plant Analog of the Mammalian Inhibitor of eIF-2a Phosphorylation. Translational Control Symposium. Cold Spring Harbor, NY; 1996.
70.
Kibler K.V., Langland J.0., Shors T., Zeman C.C. and Jacobs B.L. A Double-Stranded RNA-Binding Protein is Necessary to Inhibit Induction of Apoptosis and for Interferon-Resistance in Vaccinia Virus Infected Cells. American Society for Virology. London, Canada; 1996.
71.
Kibler K., Langland J., Shors T., Zeman C., Perkins K., and Jacobs B. Evidence that dsRNA is a Trigger for Apoptosis in Vaccinia-Virus Infected HeLa Cells. American Society of Microbiology. Arizona; 1996.
72.
Jacobs B.L., Langland J.0., and Kibler K. Vaccinia Virus Regulation of Apoptosis. International Congress on Virology. Jerusalem, Israel; 1996.
73.
Roth D.A., Langland L.A. and Langland J.0. Substrate Phosphorylation by the Plant Encoded, dsRNA-Stimulated Protein Kinase. American Society for Virology. Austin, TX; 1995.
74.
Langland J.0. , Langland L.A. and Roth D.A. Regulation of the Plant-Encoded, dsRNA-Dependent Protein Kinase, pPKR, Activity and Protein Levels by Virus Infection. American Society for Virology. Austin, TX; 1995.
75.
Langland J.0., Langland L.A. and Roth D.A. Interaction of the Plant Encoded, dsRNA-Dependent Protein Kinase with an Inhibitor of eIF-2a Phosphorylation. American Phytopathological Society. Jackson, WY; 1995.
76.
Langland J.0., Jacobs B.L. and Roth D.A. A Plant Protein Kinase with Properties Similar to the Mammalian Interferon-induced, Double-Stranded RNA Dependent Protein Kinase. American Society for Virology. Madison, WI; 1995.
77.
Kibler K.V., Langland J.0., Shors T., Malley G. and Jacobs B.L. Induction of Apoptosis in HeLa Cells Infected with Variants of Vaccinia Virus. American Society for Virology. Austin, TX; 1995.
78.
Langland J.0., Jin S., Jacobs B. and Roth D. A Plant Cell Encoded Double-Stranded RNA Binding Protein with Properties Similar to the Interferon-Induced, Double-Stranded RNA-Dependent Protein Kinase. Keystone Symposium. Durango, CO; 1994.
79.
Jacobs B., Chang C., Shors S., Shors T., Denzler K., and Langland J. Characterization of a Protein Motif Necessary for Specific Binding to Double-Stranded RNA. Keystone Symposium. Durango, CO; 1994.
80.
Langland J.0., Pettiford S. and Jacobs B.L. Protein Binds Specifically to Double-Stranded RNA and Inhibits the Interferon-induced Protein Kinase. American Society for Virology. Davis, CA; 1993.
81.
Langland J.0., Jacobs B.L. Cellular and Viral Regulation of the Interferon-induced, Double-Stranded RNA Dependent Protein Kinase. Department of Molecular Biology Seminar Series; University of Wyoming. Laramie, WY; 1993.
82.
Pettiford S., Langland J.0. and Jacobs B.L. The Rotavius Group C NS-34 Protein Specifically Binds Double-stranded RNA. Arizona State University Life Sciences Conference. Tontozona, AZ; 1992.
83.
Park H., Langland J.0., Jacobs B.L. and Venkatesan S. An RRE Binding Cellular Factor Which is Identical to the Tar Binding Protein, TRBP, Has a Broad Range of RNA Affinities and Has No Effect on HIV Tat or Rev Function, But is an Inhibitor of Double-Stranded RNA Activated Protein Kinase in Vitro. Cold Spring Harbor, NY; 1992.
84.
Langland J.0., Pettiford S. and Jacobs B.L. The Porcine Rotavirus NS34 Protein Binds Specifically to Double-Stranded RNA. International Symposium on Double-Stranded RNA Viruses. Scottsdale, AZ; 1992.
85.
Langland J.0. and Jacobs B.L. The Phosphorylation State of the Interferon-Induced Protein Kinase. American Society for Virology. Salt Lake City, UT; 1990.
86.
Langland J.0. and Jacobs B.L. Identification of Two Forms of the Interferon-induced Protein Kinase. American Society for Virology. Austin, TX; 1989.
87.
Langland J.0. and Jacobs B.L. Identification of Two Forms of the Interferon-induced Protein Kinase. Arizona State University Life Sciences Conference. Tontozona, AZ; 1989.